TLR1 and colorectal carcinoma: In conclusion, our results indicate that dysfunctional TLR1 reduces the extent of antitumor immunity elicited by immunogenic chemotherapy, leading to poor response to OXP and worse survival outcomes in locally advanced CRC patients.